Trevi Therapeutics
TRVI

Trevi Therapeutics (TRVI) news

Recent news

Webuild buys 607,496 Trevi shares at EUR 5.165/shr

Webuild has acquired 607,496 shares in Trevi at a price of EUR 5.165 per share, according to recent market activity. The transaction represents a significant investment in the company, reflecting confidence in its strategic direction and operational performance. Share ownership typically conveys…

AInvest Wire · 3d ago

Webuild - Voluntary public tender offer for shares of Trevi

Webuild, an Italian construction and infrastructure company, has announced a voluntary public tender offer for shares of Trevi, another major player in the construction sector. The offer aims to acquire a controlling stake in Trevi and has been revised to meet the conditions required for the…

AInvest Wire · 3d ago

Webuild Spain - Holds 28.79% of Trevi share capital

Webuild Spa has increased its stake in Trevi-Finanziaria Industriale to 28.79% of the company’s share capital, according to recent developments in the ongoing takeover contest. This follows a strategic move by Webuild to raise its tender offer price from €4.50 to 49% premium over the reference…

AInvest Wire · 3d ago

Freshworks Inc: Freshworks to extend FreshService into AI, software spend governance with pact to buy Torii

AInvest Wire · 3d ago

Webuild says iCop Trevi bid worth EUR 4.587/share as of Oct 9

Webuild S.p.A. has reaffirmed its tender offer for Trevi – Finanziaria Industriale S.p.A., valuing each share at €4.50 in cash, a price that remains unchanged despite recent developments in the takeover battle . As of October 9, 2026, this offer represents a 29.8% premium over the official price of…

AInvest Wire · 5d ago

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.